{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:38:20Z","timestamp":1769751500453,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00432-018-2610-z","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T15:23:00Z","timestamp":1518880980000},"page":"901-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"2610_CR1","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman O (2017a) Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. HPB (Oxford)","DOI":"10.1016\/j.hpb.2017.08.017"},{"issue":"2","key":"2610_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/17474124.2017.1259563","volume":"11","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O (2017b) Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis. Expert Rev Gastroenterol Hepatol 11(2):183\u2013189","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2610_CR3","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman O, Elsayed Z (2017) External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (3)","DOI":"10.1002\/14651858.CD011314.pub2"},{"issue":"1","key":"2610_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.12.013","volume":"91","author":"O Abdel-Rahman","year":"2014","unstructured":"Abdel-Rahman O, Fouad M (2014) Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 91(1):1\u20138","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2610_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","volume":"11","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Lamarca A (2017) Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol 11(1):75\u201383","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"15S","key":"2610_CR6","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1200\/jco.2009.27.15_suppl.4580","volume":"27","author":"J Bruix","year":"2009","unstructured":"Bruix J, Cheng A, Kang Y, Tsao C, Qin S, Lentini G et al (2009) Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: Analysis of two phase III, randomized, double-blind trials. J Clin Oncol 27(15S):4580-","journal-title":"J Clin Oncol"},{"issue":"1","key":"2610_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334","journal-title":"Lancet Oncol"},{"issue":"22","key":"2610_CR8","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1002\/cncr.30237","volume":"122","author":"SP Choo","year":"2016","unstructured":"Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX (2016) Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 122(22):3430\u20133446","journal-title":"Cancer"},{"issue":"5","key":"2610_CR9","doi-asserted-by":"publisher","first-page":"E359-86","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359-86","journal-title":"Int J Cancer"},{"issue":"6","key":"2610_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J Clin Oncol 33(6):550\u2013558","journal-title":"J Clin Oncol"},{"key":"2610_CR11","doi-asserted-by":"crossref","unstructured":"Lamarca A, Abdel-Rahman O, Salu I, McNamara MG, Valle JW, Hubner RA (2016) Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol","DOI":"10.1007\/s12094-016-1537-6"},{"issue":"4","key":"2610_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"61","key":"2610_CR13","doi-asserted-by":"publisher","first-page":"103077","DOI":"10.18632\/oncotarget.21528","volume":"8","author":"A Lue","year":"2017","unstructured":"Lue A, Serrano MT, Bustamante FJ, Inarrairaegui M, Arenas JI, Testillano M et al (2017) Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 8(61):103077\u2013103086","journal-title":"Oncotarget"},{"issue":"6","key":"2610_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","volume":"65","author":"JA Marrero","year":"2016","unstructured":"Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP et al (2016) Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol 65(6):1140\u20131147","journal-title":"J Hepatol"},{"issue":"5","key":"2610_CR15","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B, Durand J-P, Boudou-Rouquette P, Michels J et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7(5):e37563","journal-title":"PLoS One"},{"key":"2610_CR16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","volume":"47","author":"S Mittal","year":"2013","unstructured":"Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl):S2\u2013S6","journal-title":"J Clin Gastroenterol"},{"key":"2610_CR17","doi-asserted-by":"crossref","unstructured":"Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I et al (2017) Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 1\u20139","DOI":"10.1080\/17474124.2018.1403898"},{"issue":"3","key":"2610_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.7150\/jca.16786","volume":"8","author":"H Nishikawa","year":"2017","unstructured":"Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H et al (2017) Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 8(3):378\u2013387","journal-title":"J Cancer"},{"key":"2610_CR19","doi-asserted-by":"crossref","unstructured":"Oweira H, Helbling D, Petrausch U et al (2017) Early stage Hepatocellular carcinoma in the elderly: a SEER database analysis. J Geriatric Oncol (in press)","DOI":"10.1016\/j.jgo.2017.03.002"},{"issue":"1","key":"2610_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/hep.28881","volume":"65","author":"ND Parikh","year":"2017","unstructured":"Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R et al (2017) Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database. Hepatology 65(1):122\u2013133","journal-title":"Hepatology"},{"issue":"15S","key":"2610_CR21","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1200\/jco.2009.27.15_suppl.4590","volume":"27","author":"S Qin","year":"2009","unstructured":"Qin S, Yang T, Tak W, Yu S, Tsao C, Kim J et al (2009) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT\/AST)\/\u03b1-fetoprotein (AFP) levels. J Clin Oncol 27(15S):4590-","journal-title":"J Clin Oncol"},{"issue":"15S","key":"2610_CR22","doi-asserted-by":"crossref","first-page":"e15547","DOI":"10.1200\/jco.2009.27.15_suppl.e15547","volume":"27","author":"J Raoul","year":"2009","unstructured":"Raoul J, Craxi A, Porta C, Lentini G, Nadel A, Voliotis D et al (2009) Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): subset analysis from the phase III SHARP trial. J Clin Oncol 27(15S):e15547","journal-title":"J Clin Oncol"},{"issue":"15S","key":"2610_CR23","doi-asserted-by":"crossref","first-page":"e15518","DOI":"10.1200\/jco.2009.27.15_suppl.e15518","volume":"27","author":"T Yang","year":"2009","unstructured":"Yang T, Qin S, Tak W, Yu S, Tsao C, Kim J et al (2009) Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): subset analysis of the Asia-Pacific (AP) study. J Clin Oncol 27(15S):e15518","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-018-2610-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2610-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2610-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:34:04Z","timestamp":1659058444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-018-2610-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2610"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2610-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"14 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by the author. The current study is fully compliant with all applicable ethical and legal standards. It complies fully with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this study is based on a publicly available data set without identifying patient information, informed consent was not needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}